Protein Language Model-Conditioned Graph Neural Networks for Multitask GPCR Ligand Activity Prediction
Journal:
bioRxiv
Published Date:
Oct 7, 2026
Abstract
Predicting ligand activity across G protein-coupled receptors (GPCRs) requires models that capture both molecular structure and receptor-specific information while remaining robust to chemical and target-domain shift. We developed a multimodal graph neural network that combines explicit ligand molecular graphs with frozen protein language model representations of GPCR sequences and jointly predicts quantitative pActivity and binary activity. The model was trained on 271,739 curated ligand-GPCR pairs spanning 183,694 ligands and 216 human GPCRs and evaluated using random, Bemis-Murcko scaffold, and strict cold-ligand partitions. With ESM-2 650M receptor embeddings, the selected model achieved mean absolute errors of 0.513 {+/-} 0.006, 0.540 {+/-} 0.006, and 0.641 {+/-} 0.005 pActivity units under random, cold-ligand, and scaffold evaluation, respectively, substantially outperforming a protein-aware fixed-feature multilayer perceptron and consistently improving quantitative prediction over a matched GINE reference. Removing receptor embeddings markedly degraded both regression and classification, whereas differences among ESM-2 35M, ESM-2 650M, and ProtT5 were comparatively small. Independent evaluation on 6,319 ChEMBL 37/BindingDB pairs revealed a substantial external domain shift, with mean absolute error increasing to approximately 0.94-0.95 despite chemically stringent internal validation. Nevertheless, receptor-specific information remained highly informative in a DRD2-DRD3 selectivity analysis: the cold-ligand ensemble achieved R2 = 0.853, Spearman{rho} = 0.916, and ROC-AUC = 0.966 for strong DRD3 selectivity, whereas the receptor-independent ablation approached chance-level discrimination. These results establish protein-language-model-conditioned molecular graph learning as a scalable strategy for GPCR bioactivity prediction while identifying chemotype novelty, external-domain transfer, and richer ligand-receptor interaction representations as key remaining challenges.